Gentbrugge, May 2, 2014 – Trinean, the leading provider of microfluidic spectrophotometry platforms, today announced that it appointed Mr. Chris van Ingen as independent board member.
“We are very pleased to be working with Chris van Ingen,” comments Philippe Stas, CEO of Trinean. “His broad experience in the life science instrumentation field will be valuable to bring Trinean in its next phase of expansion.”
“Trinean’s fully integrated instrumentation platform offers excellent opportunities to automate and simplify many life sciences workflows”, Chris van Ingen adds, “and I am looking forward working with the Trinean board and management team.”
Currently, Chris is a director of the Bruker corporation, the Promega corporation and ProteinSimple corporation. Previously, Mr. van Ingen was president of Agilent Technologies’ Bio-Analytical Measurement Group. Between 1977 and 2001, Mr. van Ingen held several senior management positions at Hewlett Packard, including Vice President of Sales and Marketing of the Chemical Analysis group.
Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the Xpose for ‘Touch & Go’ biomolecule quantification and the DropSense96®, analyzing up to 96 samples, using microfluidic chips for standardized sample analysis ( DropPlates and Xpose Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
For more information about Trinean, visit http://www.trinean.com
ir. Philippe Stas
Chief Executive Officer
Dulle Grietlaan 17/3
B-9050 Gent – Belgium